Type I Diabetes Is The Main Cost Driver In Autoimmune Polyendocrinopathy.
Autoimmune polyendocrinopathy (AP), a chronic complex orphan disease, encompasses at least two autoimmune-induced endocrine diseases. To estimate for the first time total, indirect and direct costs for patients with AP, as well as cost drivers. Cross-sectional cost of illness study. Academic tertiary referral center for AP. 146 consecutive, unselected AP patients. Interviews pertaining to patients' socioeconomic situation covered a recall period of 12 months. Both the Human Capital (HCA) and the Friction Cost Approaches (FCA) were applied as estimation methods. Direct and indirect annual costs, sick leave- and medication costs. AP markedly impacts health care expenses. Mean overall costs of AP in Germany ranged from €5,971,090 to €29,848,187 per year (HCA). Mean indirect costs ranged from €3,388,284 to €16,937,298 per year (HCA) while mean direct costs ranged from €2,582,247 to €12,908,095/year. Mean direct costs per year were €1851 in AP patients with type 1 diabetes (T1D, 76%) and €671 without T1D, which amounts to additional direct costs of €1209 for T1D when adjusting for concomitant autoimmune disease (95%-CI = €1,026 - €1,393, p<0.0001). Sick leave cost estimates for AP patients with T1D exceeded those without T1D by 70% (FCA) and 43% (HCA), respectively. In multiple regression analyses, T1D predicted total and direct costs, medication costs and costs for diabetic devices (all p<0.001). Overall, AP patients with T1D were 54% (FCA) more expensive than those without T1D. Public health socioeconomic relevance of AP was demonstrated, with T1D as main cost driver.